Numerous in vivo and in vitro studies have indicated that it plays a promoting role in the pathogenesis of osteoporosis, including the suppression of osteogenic differentiation by increasing the expression of miR-92b-3p, affecting the β-catenin and Runx2/Smad signaling pathways during osteogenesis, and activating the NF-κB and ERK pathways to produce cytotoxicity and pro-inflammatory responses, among others. This evidence concerns the gene MAPK1 and osteoporosis.